Fingerprint
Dive into the research topics of 'Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
Geundoo Jang, Dok Hyun Yoon, Shin Kim, Dae Ho Lee, Sang Wook Lee, Jooryung Huh, Cheolwon Suh
Research output: Contribution to journal › Article › peer-review
14
Scopus
citations